Stifel Nicolaus Lowers Pyxis Oncology (NASDAQ:PYXS) Price Target to $8.00

Key Points

• Stifel Nicolaus lowered its price target on Pyxis Oncology (NASDAQ: PYXS) from $9.00 to $8.00 while keeping a "buy" rating, with that target implying roughly a 455.56% upside from the stock's current price.
• Analyst consensus is a "Moderate Buy" (five Buys, one Hold, one Sell) with a $7.00 consensus price target; PYXS traded around $1.44 midday (market cap ~$89.7M) and recently reported EPS of ($0.29) versus an expected ($0.35) and quarterly revenue of $11.04M.
• Pyxis is a clinical‑stage biotech focused on antibody‑drug conjugates (ADCs) for solid tumors, and about 39% of the stock is held by hedge funds and other institutional investors, several of which have recently increased positions.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) had its price objective cut by stock analysts at Stifel Nicolaus from $9.00 to $8.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Stifel Nicolaus' price target indicates a potential upside of 455.56% from the stock's current price.

Several other analysts have also weighed in on the company. Wall Street Zen lowered Pyxis Oncology from a "hold" rating to a "sell" rating in a report on Sunday, March 15th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Pyxis Oncology in a research note on Thursday, January 22nd. Royal Bank Of Canada lowered their price objective on shares of Pyxis Oncology from $8.00 to $5.00 and set an "outperform" rating on the stock in a research note on Thursday, December 18th. HC Wainwright restated a "buy" rating and set a $7.00 target price on shares of Pyxis Oncology in a report on Tuesday. Finally, Stephens lifted their target price on shares of Pyxis Oncology from $5.00 to $8.00 and gave the stock an "overweight" rating in a research report on Monday, November 24th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $7.00.

Pyxis Oncology Price Performance

Shares of PYXS stock traded up $0.02 during midday trading on Tuesday, reaching $1.44. 63,797 shares of the company traded hands, compared to its average volume of 721,289. The firm's 50 day simple moving average is $1.53 and its two-hundred day simple moving average is $2.52. Pyxis Oncology has a 1-year low of $0.83 and a 1-year high of $5.55. The firm has a market cap of $89.65 million, a PE ratio of -0.90 and a beta of 1.45.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last announced its quarterly earnings results on Tuesday, March 24th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.06. The firm had revenue of $11.04 million for the quarter. As a group, research analysts anticipate that Pyxis Oncology will post -1.04 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP raised its position in shares of Pyxis Oncology by 37.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 50,066 shares of the company's stock valued at $58,000 after buying an additional 13,550 shares during the last quarter. HRT Financial LP grew its stake in Pyxis Oncology by 157.5% in the 4th quarter. HRT Financial LP now owns 39,649 shares of the company's stock worth $45,000 after acquiring an additional 24,251 shares during the period. XTX Topco Ltd purchased a new stake in Pyxis Oncology in the 2nd quarter worth approximately $40,000. LPL Financial LLC raised its holdings in Pyxis Oncology by 150.7% in the 4th quarter. LPL Financial LLC now owns 35,102 shares of the company's stock valued at $40,000 after acquiring an additional 21,100 shares during the last quarter. Finally, Engineers Gate Manager LP purchased a new position in shares of Pyxis Oncology during the 4th quarter worth $26,000. 39.09% of the stock is currently owned by hedge funds and other institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology NASDAQ: PYXS is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company's platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.